GSK Overall Survival Data Clinches Role For BRAF/MEK Combo In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
In the COMBI-v study, BRAF/MEK combination Tafinlar/Mekinist improves overall survival by 31% compared to BRAF monotherapy. GSK’s combination and Genentech’s cobimetinib/Zelboraf combination both improve progression-free survival and reduce cutaneous malignancies compared to monotherapy.